In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At APA, Neuronetics Launches TMS

Executive Summary

For millions of Americans who suffer from moderate to severe depression-and millions more around the world-existing drug therapies don't provide adequate treatment. For some, the drugs simply don't work; for others, the drugs treat their depression, but their side effects are so debilitating that the cure is worse than the disease. Now, Neuronetics says it has a new approach to depression treatment, one based on the focused delivery of magnetic energy, that works for these otherwise untreatable patients. More importantly, the company claims, it now has the data to prove it.
Advertisement

Related Content

Neuronetics Inc.
Neuronetics Inc.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel